Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical ...

VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund ...

Insider buying matters in every industry, but it carries a special weight in biotechnology. In most businesses, management has a reasonably clear view of sales trends, margins, customer demand, and ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Lixte Biotechnology (ISIN: US53833K1060) develops novel cancer therapies targeting key tumor regulators. North American investors eye its clinical-stage assets amid biotech volatility. Understand the ...